DC
CADL icon

Davenport & Co’s Candel Therapeutics CADL Stock Holding History

Davenport & Co’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
+10,200
New +$77K ﹤0.01% 1342

Other funds holding CADL

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
LF
LifeSteps Financial Claremont, California $215M AUM 27.52% 1-Year Est. Return

Davenport & Co's CADL Position: Q2 2026 in Review

Davenport & Co opened a new position in Candel Therapeutics (CADL) in Q2 2026: 10,200 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #1342 among its holdings.

6 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Davenport & Co held 10,200 shares of Candel Therapeutics worth $105K as of Q2 2026.
  • Candel Therapeutics was a new Davenport & Co position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #1342 holding.
  • 6 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.